Release Date:

March 31, 2020

Expiration Date:

May 31, 2021

Target Audience

This initiative is designed to educate health care providers involved in the management of patients with pain, including but not limited to physicians in primary care, pain management, anesthesiology, surgery, oncology, hematology-oncology, emergency medicine, and psychiatry; physicians who treat high-risk populations, such as veterans and active service members; advanced practitioners, nurse practitioners, physician assistants, and nurses; and pharmacists.

Learning Objectives

At the completion of this course, the learner should be able to:

1. Demonstrate familiarity with foundational concepts in the understanding of pain
2. Review the elements and importance of comprehensive assessment of patients with chronic pain
3. Describe how to create individualized treatment plans for patients with chronic pain
4. Review the role of nonpharmacologic therapies and nonopioid analgesics in managing chronic pain
5. Demonstrate familiarity with the pharmacologic properties of opioid analgesics
6. Discuss the risks associated with opioid use
7. Describe the safe initiation of opioid therapy in patients with acute and chronic pain, including risk assessment
8. Recognize patient populations in whom chronic pain management with opioids may pose additional challenges
9. List key safety strategies for patients prescribed opioids, including proper storage and disposal
10. Structure follow-up assessments for patients on opioid therapy
11. Explain how to modify doses of opioids based on analgesic efficacy
12. Recognize when and how to discontinue use of opioids
13. Conduct ongoing risk assessment in patients on long-term opioid therapy
14. Identify signs of opioid use disorder in patients undergoing therapy
15. Demonstrate familiarity with the general concepts of addiction medicine
16. Demonstrate familiarity with key messages around safe opioid-taking practices that should be communicated to patients
17. Describe relevant scientific concepts to patients using appropriate language and tone
18. Assess the utility of patient-prescriber agreements and other documentation in the patient record

Accreditation Statements

CME/CE credit provided by AKH Inc., Advancing Knowledge in Healthcare. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Warrior Centric Healthcare Foundation.

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Warrior Centric Healthcare Foundation. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

Nurses

AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Each activity is awarded 0.5 contact hour.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Warrior Centric Healthcare Foundation.
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803.
Each activity is approved for 0.5 contact hour which includes 0.5 hour of pharmacology.
Each activity was planned in accordance with AANP Accreditation Standards and Policies.

Pharmacy

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AKH Inc., Advancing Knowledge in Healthcare approves each knowledge-based activity for 0.5 contact hour (0.05 CEU).

Criteria for Success

To obtain credit, a score of 67% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You will have no more than 4 attempts to successfully complete the post-test.

If you have questions about this CME/CE activity, please contact AKH Inc. at service@akhcme.com.

Faculty

Chair

Charles E. Argoff, MD

Professor of Neurology
Albany Medical Center
Albany, New York

Yvonne D’Arcy, CRNP, CNS

Pain Management & Palliative Care Nurse Practitioner
Suburban Hospital-Johns Hopkins Medicine
Bethesda, Maryland

Jeffrey Fudin, PharmD, FCCP, FASHP, FFSMB

Director, PGY2 Pain Residency, Stratton VA Medical Center
Adjunct Associate Professor, Western New England University College of Pharmacy
Adjunct Assistant Professor of Pharmacy Practice, University of Connecticut School of Pharmacy
Founder and Manager, Pharmacist Consulting Services, PLLC
Albany, New York

Marc R. Gerber, MD

MRG Rehabilitation & Pain Medicine
Assistant Clinical Professor
University of Central Florida College of Medicine
Orlando, Florida

Evelyn L. Lewis, MD, MA, FAAFP, DABDA

Chair
Warrior Centric Healthcare Foundation
Rockville, Maryland

Bill H. McCarberg, MD, FABM

Kaiser Permanente San Diego (retired)
Assistant Clinical Professor
University of California
San Diego, California

Amelia L. Persico, PharmD, MBA

PGY2 Pain and Palliative Care Resident
Stratton Veterans Administration Medical Center
Albany, New York

Independent Reviewer

Lynn Webster MD, FACPM, FASAM

Vice President of Scientific Affairs
PRA Healthsciences
Salt Lake City, Utah

Commercial Support

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Faculty

• Charles E. Argoff, MD:

  Allergan plc, Amgen Inc., Biohaven Pharmaceutical, Eli Lilly and Company, Flowonix Medical, Novartis, Teva Pharmaceutical Industries Ltd (speakers’ bureaus); Pfizer Inc., Trevena Inc (stock)

• Yvonne D’Arcy, CRNP, CNS:

  Salix Pharmaceuticals (speakers bureau); Eli Lilly and Company; Pfizer Inc (consultant); Springer Publishing (royalties)

• Jeffrey Fudin, PharmD, FCCP, FASHP, FFSMB:

  Abbott Laboratories, AcelRx Pharmaceuticals, Acutis Diagnostics, Inc, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals (speaker); AcelRx Pharmaceuticals, BioDelivery Sciences International, Daiichi Sankyo, GlaxoSmithKline, Human Half-Cell, Inc, Quest Diagnostics, Salix Pharmaceuticals (advisory boards); AcelRx Pharmaceuticals, BioDelivery Sciences International, Daiichi Sankyo, Firstox Laboratories (consultant); GlaxoSmithKline, Scilex Pharmaceuticals, Salix Pharmaceuticals (presentations/publications)

• Marc R. Gerber, MD:

  Nothing to disclose

• Evelyn L. Lewis, MD, MA, FAAFP, DABDA:

  Nothing to disclose

• Bill H. McCarberg, MD, FABM:

  Nothing to disclose

• Amelia L. Persico, PharmD, MBA:

  Nothing to disclose

• Lynn Webster MD, FACPM, FASAM:

  Daiichi Sankyo, Insys, Mallinckrodt, Merck, Pain Therapeutics, Pfizer, Shionogi, Teva, Trevena, Vallon (consultant); BDSI, Ensysce Biosciences, Mallinckrodt, Pfizer, Trevena (advisory boards)

Reviewers

• Dorothy Duffy, PharmD, Pharmacy Reviewer

  discloses no financial relationships with pharmaceutical or medical product manufacturers.

• Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner

  discloses no financial relationships with pharmaceutical or medical product manufacturers.

• Bernadette Makar, MSN, APRN-BC, NP-C, Nurse Planner

  discloses no financial relationships with pharmaceutical or medical product manufacturers.

• AKH staff, planners, and reviewers

  have no relevant financial relationships to disclose.

• Warrior Centric Healthcare Foundation staff and planners

  have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Warrior Centric Healthcare Foundation


This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).


Distributed by www.cmezone.com and www.MyCME.com